Faruqi & Faruqi Investigates Possible Claims Against Regeneron Pharmaceuticals for Investor Protection
In a significant move to safeguard investor rights, Faruqi & Faruqi, LLP, a nationally recognized securities law firm, has initiated an investigation into Regeneron Pharmaceuticals, Inc. The investigation is centered around allegations of possible violations of federal securities laws by Regeneron and its executives. The firm is actively encouraging investors who experienced financial losses from purchasing or acquiring Regeneron securities between November 2, 2023, and October 30, 2024, to reach out to them for a discussion of their legal options. This proactive stance is particularly timely as the firm reminds investors of the approaching March 10, 2025, deadline for seeking lead plaintiff status in a federal securities class action against the company.
The complaints emerging from this investigation suggest severe misconduct on the part of Regeneron. The allegations assert that the company made misleading statements or failed to disclose crucial information concerning its business practices. Specifically, it is claimed that during the specified period, Regeneron paid credit card fees to distributors under the condition that these distributors would not charge patients more for Eylea when paying via credit card. This behavior is believed to have effectively subsidized the prices that patients were required to pay, thus misleadingly inflating sales figures for Eylea, a key anti-VEGF treatment offered by the company. This sort of action, if proven true, could bring serious ramifications as it violates the False Claims Act.
Compounding the situation was the announcement by the U.S. Department of Justice (DOJ) on April 10, 2024, regarding charges filed against Regeneron under the False Claims Act. The DOJ's complaint criticizes Regeneron for allegedly failing to report millions in discounts that were provided to drug distributors in the form of reimbursed credit card fees. This failure not only raised concerns about the inflated Average Selling Price (ASP) for the Eylea treatment but also suggested that these practices wrongfully increased Medicare reimbursement amounts. As a direct result of these claims, Regeneron witnessed a substantial drop in its stock price, which indicates the market's severe reaction to the unfolding situation.
On October 31, 2024, Regeneron released its third-quarter financial results, which further revealed disappointing sales figures for Eylea, greatly missing analyst expectations. This shortfall led to a drastic drop in the stock price, signaling the negative impact of the previous disclosures on investor confidence.
In light of these troubling developments, Faruqi & Faruqi remains committed to ensuring that affected investors receive the justice they deserve. They stress the importance of investor participation in this potential class action. Becoming the lead plaintiff can significantly influence the direction of the litigation and ensures that the case receives the attention it warrants in court. Investors are encouraged to either participate in this role or to remain informed about the progressing case by staying in contact with the firm.
Faruqi & Faruqi is known for its robust track record, having recovered millions for investors since its inception in 1995. The firm operates on the principle that transparency in corporate governance is paramount and that investors should always have the support they require during trying times. This investigation is not just about correcting past wrongs; it is about safeguarding futures and endorsing accountability in the corporate sector.
If you believe you have been affected by the alleged actions of Regeneron Pharmaceuticals, you are urged to contact Faruqi & Faruqi. The firm is particularly interested in gathering information, including from whistleblowers, former employees, and other shareholders. To learn more about the ongoing investigation and the class action lawsuit against Regeneron, visit www.faruqilaw.com/REGN or get in touch directly with attorney Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
The complaints emerging from this investigation suggest severe misconduct on the part of Regeneron. The allegations assert that the company made misleading statements or failed to disclose crucial information concerning its business practices. Specifically, it is claimed that during the specified period, Regeneron paid credit card fees to distributors under the condition that these distributors would not charge patients more for Eylea when paying via credit card. This behavior is believed to have effectively subsidized the prices that patients were required to pay, thus misleadingly inflating sales figures for Eylea, a key anti-VEGF treatment offered by the company. This sort of action, if proven true, could bring serious ramifications as it violates the False Claims Act.
Compounding the situation was the announcement by the U.S. Department of Justice (DOJ) on April 10, 2024, regarding charges filed against Regeneron under the False Claims Act. The DOJ's complaint criticizes Regeneron for allegedly failing to report millions in discounts that were provided to drug distributors in the form of reimbursed credit card fees. This failure not only raised concerns about the inflated Average Selling Price (ASP) for the Eylea treatment but also suggested that these practices wrongfully increased Medicare reimbursement amounts. As a direct result of these claims, Regeneron witnessed a substantial drop in its stock price, which indicates the market's severe reaction to the unfolding situation.
On October 31, 2024, Regeneron released its third-quarter financial results, which further revealed disappointing sales figures for Eylea, greatly missing analyst expectations. This shortfall led to a drastic drop in the stock price, signaling the negative impact of the previous disclosures on investor confidence.
In light of these troubling developments, Faruqi & Faruqi remains committed to ensuring that affected investors receive the justice they deserve. They stress the importance of investor participation in this potential class action. Becoming the lead plaintiff can significantly influence the direction of the litigation and ensures that the case receives the attention it warrants in court. Investors are encouraged to either participate in this role or to remain informed about the progressing case by staying in contact with the firm.
Faruqi & Faruqi is known for its robust track record, having recovered millions for investors since its inception in 1995. The firm operates on the principle that transparency in corporate governance is paramount and that investors should always have the support they require during trying times. This investigation is not just about correcting past wrongs; it is about safeguarding futures and endorsing accountability in the corporate sector.
If you believe you have been affected by the alleged actions of Regeneron Pharmaceuticals, you are urged to contact Faruqi & Faruqi. The firm is particularly interested in gathering information, including from whistleblowers, former employees, and other shareholders. To learn more about the ongoing investigation and the class action lawsuit against Regeneron, visit www.faruqilaw.com/REGN or get in touch directly with attorney Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.